CAPR
Capricor Therapeutics, Inc.
There isn't enough reported data to score CAPR yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CAPR Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
CAPR's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CAPR PE Valuation
CAPR has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CAPR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CAPR's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CAPR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.64 | -$0.89 |
| Q2 2026 | -$2.45 | -$0.86 |
| Q1 2026 | -$2.32 | -$0.95 |
| Q4 2025 | -$2.26 | -$1.11 |
| Q3 2025 | -$1.75 | -$0.68 |
| Q2 2025 | -$1.59 | -$0.65 |
| Q1 2025 | -$1.37 | -$0.49 |
| Q4 2024 | -$1.15 | -$0.27 |
CAPR lost $2.64 per share over the past year, a bigger loss than the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CAPR on earnings quality, reporting a profit while its opponent remains loss making.
CAPR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $11.1M | -7.9% |
| Q3 2024 | $2.3M | -63% |
| Q2 2024 | $4M | +1.4% |
| Q1 2024 | $4.9M | +64% |
| Q4 2023 | $12.1M | +1159% |
| Q3 2023 | $6.2M | +289% |
| Q2 2021 | $204.1K | +309% |
| Q1 2021 | $40.8K | -78% |
OSCR has the stronger quarterly revenue trend. Revenue is down 7.9% for CAPR versus up 72% for OSCR.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -69% | -59 points |
| Q3 2024 | -575% | -464 points |
| Q2 2024 | -292% | -94 points |
| Q1 2024 | -209% | +65 points |
| Q4 2023 | -11% | +830 points |
| Q3 2023 | -111% | +296 points |
| Q2 2023 | -198% | N/A |
| Q1 2023 | -274% | N/A |
CAPR's operating margin was −69% last quarter, down 59 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
CAPR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37.5M | -$17.8M |
| Q2 2026 | -$35.5M | -$15.1M |
| Q1 2026 | -$34.4M | -$27M |
| Q4 2025 | -$25.2M | -$9.9M |
| Q3 2025 | -$19.7M | -$8.1M |
| Q2 2025 | -$20.4M | -$8.1M |
| Q1 2025 | -$7.3M | -$5.5M |
| Q4 2024 | -$15.3M | -$3.1M |
CAPR has burned cash in almost every quarter: −$133M over the past year, against −$63M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CAPR on cash generation, producing positive trailing cash flow while its opponent burns cash.
CAPR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +202K shares |
| 1 year | +27% | +12.4M shares |
| 3 years | +129% | +32.8M shares |
| 5 years | +154% | +35.3M shares |
| Available history | +745% | +51.2M shares |
CAPR has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CAPR Net Leverage
CAPR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CAPR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 67.4 | Neutral |
CAPR's weekly RSI is 44 (neutral) and its Stochastic is 67 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CAPR PE vs Healthcare Sector
CAPR has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CAPR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.92 | 29% above |
| 20 week MA | $10.2 | 0.1% above |
| 50 week MA | $20.9 | 51% below |
| 100 week MA | $15.5 | 34% below |
| 200 week MA | $10.8 | 5.4% below |
CAPR has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 5.4% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CAPR on trend strength, trading above more of its moving averages.
CAPR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.16 | $3.90 | +236% |
| 2021 | $3.90 | $3.39 | -13% |
| 2022 | $3.39 | $3.52 | +3.8% |
| 2023 | $3.52 | $4.89 | +39% |
| 2024 | $4.89 | $14.1 | +188% |
| 2025 | $14.1 | $29.7 | +111% |
| 2026 YTD | $29.7 | $10.2 | -66% |
CAPR is down 66% so far in 2026, after finishing higher in five of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CAPR on returns for 2026, with the stronger performance.